# EDGAR Filing Document

**Accession Number:** 0001971543
**File Stem:** 0001193125-25-139898
**Filing Date:** 2025-6
**Character Count:** 5779
**Document Hash:** 36772586fb48a2d4735f282bec330836
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-139898.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001193125-25-139898

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250611

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mural Oncology plc
- **CENTRAL INDEX KEY:** 0001971543
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41837
- **FILM NUMBER:** 251042687

**BUSINESS ADDRESS:**
- **STREET 1:** 10 EARLSFORT TERRACE
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 T380
- **BUSINESS PHONE:** 353 1 905 8020

**MAIL ADDRESS:**
- **STREET 1:** 10 EARLSFORT TERRACE
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 T380

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mural Oncology Ltd
- **DATE OF NAME CHANGE:** 20230403

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pistachiovale Ltd
- **DATE OF NAME CHANGE:** 20230329

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### Current Report

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of Earliest Event Reported): June 11, 2025

## Mural Oncology plc

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Ireland** | **001-41837** | **98-1748617** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **10 Earlsfort Terrace**<br> **Dublin 2, D02 T380, Ireland** | **Not Applicable** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: +353-1-905-8020

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Ordinary Shares, nominal value $0.01 | MURA | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.**  |

---

On June 11, 2025, Mural Oncology plc (the "Company") held its 2025 annual general meeting (the "AGM"). Below are the voting results for the proposals submitted to the Company's shareholders for a vote at the AGM.

#### PROPOSAL 1. – ELECTION OF DIRECTORS
In accordance with the Company's Constitution, as amended, the Company's shareholders elected, by separate resolutions, six directors to serve until the Company's 2026 annual general meeting, as set forth below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Director Nominees** | **For** | **Against** | **Abstain** | **Broker Non-Votes** |
|  Francis Cuss, M.B., B.Chir., FRCP | 5883909 | 596030 | 2488 | 5657632 |
|  George Golumbeski, Ph.D. | 5713441 | 764765 | 4221 | 5657632 |
|  Benjamin Hickey, MBA | 5884908 | 594065 | 3454 | 5657632 |
|  Scott Jackson, MBA | 5879630 | 601008 | 1789 | 5657632 |
|  Caroline Loew, Ph.D. | 5886901 | 614239 | 1287 | 5657632 |
|  Sachiyo Minegishi, MBA | 5883528 | 593623 | 5276 | 5657632 |

---

#### PROPOSAL 2. – RATIFICATION OF SELECTION OF INDEPENDENT AUDITOR
The Company's shareholders ratified, in a non-binding vote, the selection of PricewaterhouseCoopers LLP as the Company's independent auditor for the fiscal year ending December 31, 2025 and authorized, in a binding vote, the Company's board of directors, acting through the audit committee, to set the independent auditor's remuneration, as set forth below:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 11918446 | 190443 | 31171 |  |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Mural Oncology plc** | **Mural Oncology plc** |
| Dated: June 12, 2025 | By: | /s/ Maiken Keson-Brookes |
|  | Name: | Maiken Keson-Brookes |
|  | Title: | Chief Legal Officer |

---